Trial Profile

An Expanded Access program (EAP) of OT-101 in pancreatic cancer

Status: Planning

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabedersen (Primary)
Indications Pancreatic cancer
Focus Expanded access; Therapeutic Use

Most Recent Events

13 Sep 2019 New trial record
09 Sep 2019 According to a Mateon Therapeutics media release, the company has executed agreements with WideTrial Inc. for an Expanded Access program (EAP) in pancreatic cancer. The partnership may also support Expanded Access for OT-101 in additional patients with advanced solid tumors, excluding brain cancers (AA, GBM, and other gliomas).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com